Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co (LLY)

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co, reports the sale of a portion of its common stock holdings on February 21, 2025.

Summary

• Lilly Endowment Inc. filed a Form 4 with the SEC on February 24, 2025, reporting changes in beneficial ownership of Eli Lilly & Co (LLY) common stock.
• On February 21, 2025, Lilly Endowment Inc. sold a total of 96,547,424 shares in multiple transactions.
• The sales were executed at weighted average prices ranging from $877.313 to $893.75 per share.
• Following these transactions, Lilly Endowment Inc. still beneficially owns 96,522,410 shares of Eli Lilly & Co.
• The filing indicates that these transactions were sales of common stock and did not involve derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a sale of shares; it doesn't inherently convey positive or negative sentiment, but rather provides factual information about transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC when significant shareholders or insiders of a publicly traded company alter their ownership positions; this filing provides transparency to the market regarding the transactions of a major Eli Lilly & Co shareholder.

Stakeholder Impact

• The sale of a significant number of shares by a major shareholder like Lilly Endowment Inc. could potentially exert downward pressure on Eli Lilly & Co's stock price in the short term.
• The filing provides transparency to shareholders regarding the transactions of a major shareholder.

Key Dates

Keywords

Form 4, Beneficial Ownership, Share Sales, Lilly Endowment Inc., Eli Lilly & Co, LLY, SEC Filing, Common Stock